Literature DB >> 32162050

[Systemic drug treatment during pregnancy].

Maximilian Riedel1, Bettina Kuschel2.   

Abstract

In clinical routine, treatment of pregnant women is a recurring challenge. The frequent opacity of current studies, lack of reliable sources of information and the general insecurity of pregnant women towards systemic drug treatment leads to difficult clinical decision making. Potent therapies with sufficient clinical experience in terms of safety of application are available for most diseases seen in pregnancy. After careful evaluation of potential benefits and risks of a therapy, not only the optimal choice of a medical treatment, but also adequate control of clinical symptoms and interdisciplinary care are crucial for a safe pregnancy.

Entities:  

Keywords:  Benefit-risk assessment; Contraindication; Medication; Pregnancy; Safety

Mesh:

Substances:

Year:  2020        PMID: 32162050     DOI: 10.1007/s00105-020-04560-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.

Authors:  Emmanuel Bujold; Stéphanie Roberge; Yves Lacasse; Marc Bureau; François Audibert; Sylvie Marcoux; Jean-Claude Forest; Yves Giguère
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

2.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient.

Authors:  K A Aleck; D L Bartley
Journal:  Am J Med Genet       Date:  1997-10-31

3.  Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome.

Authors:  J Román Corona-Rivera; Alejandro Rea-Rosas; Adrián Santana-Ramírez; Jorge Acosta-León; Juan Hernández-Rocha; Karla Miguel-Jiménez
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

Review 4.  Safety of Topical Corticosteroids in Pregnancy.

Authors:  Ching-Chi Chi; Shu-Hui Wang; Gudula Kirtschig
Journal:  JAMA Dermatol       Date:  2016-08-01       Impact factor: 10.282

5.  Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.

Authors:  Corinna Weber-Schoendorfer; Marc Oppermann; Evelin Wacker; Nathalie Bernard; Delphine Beghin; Benedikte Cuppers-Maarschalkerweerd; Jonathan L Richardson; Laura E Rothuizen; Alessandra Pistelli; Heli Malm; Georgios Eleftheriou; Debra Kennedy; Mine Kadioglu Duman; Reinhard Meister; Christof Schaefer
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 6.  An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses.

Authors:  Angela E Lin; Kathryn E Singh; Arthur Strauss; Son Nguyen; Kristyn Rawson; Virginia E Kimonis
Journal:  Am J Med Genet A       Date:  2011-03-15       Impact factor: 2.802

7.  Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism.

Authors:  Morten Søndergaard Jensen; Cristina Rebordosa; Ane Marie Thulstrup; Gunnar Toft; Henrik Toft Sørensen; Jens Peter Bonde; Tine Brink Henriksen; Jørn Olsen
Journal:  Epidemiology       Date:  2010-11       Impact factor: 4.822

Review 8.  Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature.

Authors:  Marlene T Anderka; Angela E Lin; Dianne N Abuelo; Allen A Mitchell; Sonja A Rasmussen
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

9.  Trial of early neonatal hydrocortisone: two-year follow-up.

Authors:  Outi M Peltoniemi; Aulikki Lano; Riina Puosi; Anneli Yliherva; Francesco Bonsante; M Anneli Kari; Mikko Hallman
Journal:  Neonatology       Date:  2008-10-17       Impact factor: 4.035

10.  A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery.

Authors:  D Heather Watts; Zane A Brown; Deborah Money; Stacy Selke; Meei Li Huang; Stephen L Sacks; Lawrence Corey
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

View more
  1 in total

1.  The challenge of using nanotherapy during pregnancy: Technological aspects and biomedical implications.

Authors:  Kelle Velasques Pereira; Renata Giacomeli; Marcelo Gomes de Gomes; Sandra Elisa Haas
Journal:  Placenta       Date:  2020-08-18       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.